Technological innovation and rapid reduction in sequencing costs have enabled the
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …

Epidermal growth factor receptor (EGFR) mutation is a reliable and sensitive biomarker for
EGFR-TKI therapy in non-small-cell lung cancer (NSCLC). However, detection of EGFR …

Importance Plasma genotyping of cell-free DNA has the potential to allow for rapid
noninvasive genotyping while avoiding the inherent shortcomings of tissue genotyping and …

Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …

Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based
EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and …

Introduction In the phase IV, open-label, single-arm study NCT01203917, first-line gefitinib
250 mg/d was effective and well tolerated in Caucasian patients with epidermal growth …

Background Detection of EGFR mutations in tumour tissue is the gold-standard approach to
ascertain if a patient will benefit from treatment with an EGFR tyrosine kinase inhibitor …

Background: Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and
safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal …

Purpose: Tumor genotyping is a powerful tool for guiding non–small cell lung cancer
(NSCLC) care; however, comprehensive tumor genotyping can be logistically cumbersome …

Patients with pancreatic and biliary carcinomas lack personalized treatment options, in part
because biopsies are often inadequate for molecular characterization. Cell-free DNA …